Disclosure of recovered technologies of unknown origin and biological evidence of non-human intelligence

(a) Exercise of eminent domain The Federal Government shall exercise eminent domain over any and all recovered technologies of unknown origin and biological evidence of non-human intelligence that may be controlled by private persons or entities in the interests of the public good. (b) Availability to Review Board Any and all such material, should it exist, shall be made available to the Review Board for personal examination and subsequent disclosure determination at a location suitable to the controlling authority of said material and in a timely manner conducive to the objectives of the Review Board in accordance with the requirements of this subtitle. (c) Actions of Review Board In carrying out subsection (b), the Review Board shall consider and render decisions— (1) whether the material examined constitutes technologies of unknown origin or biological evidence of non-human intelligence beyond a reasonable doubt; (2) whether recovered technologies of unknown origin, biological evidence of non-human intelligence, or a particular subset of material qualifies for postponement of disclosure under this subtitle; and (3) what changes, if any, to the current disposition of said material should the Federal Government make to facilitate full disclosure. (d) Review Board access to testimony and witnesses The Review Board shall have access to all testimony from unidentified anomalous phenomena witnesses, close observers and legacy program personnel and whistleblowers within the Federal Government’s possession as of and after the date of enactment of this Act in furtherance of Review Board disclosure determination responsibilities in section 1744(g) and subsection (c) of this section. (e) Solicitation of additional witnesses The Review Board shall solicit additional unidentified anomalous phenomena witness and whistleblower testimony and afford protections under section 1673(b) of the James M. Inhofe National Defense Authorization Act for Fiscal Year 2023 (50 U.S.C. 3373b(b)) if deemed beneficial in fulfilling Review Board responsibilities under this subtitle.